EMA Authorizes Hemophilia B Gene Therapy

Source link :

In its May 2024 meeting, the European Medicines Agency (EMA) gave the go-ahead for Durveqtix to treat severe and moderately severe hemophilia B in adults who do not have factor IX inhibitors or detectable antibodies to variant adeno-associated virus serotype Rh74 (AAVRh74var). The agency has also recommended Adzynma for the treatment of ADAMTS13 enzyme deficiency […]

Author : News Health

Publish date : 2024-05-31 16:10:06

Copyright for syndicated content belongs to the linked Source.